PH12019501885A1 - Cancer treatment - Google Patents

Cancer treatment

Info

Publication number
PH12019501885A1
PH12019501885A1 PH12019501885A PH12019501885A PH12019501885A1 PH 12019501885 A1 PH12019501885 A1 PH 12019501885A1 PH 12019501885 A PH12019501885 A PH 12019501885A PH 12019501885 A PH12019501885 A PH 12019501885A PH 12019501885 A1 PH12019501885 A1 PH 12019501885A1
Authority
PH
Philippines
Prior art keywords
film
plates
panels
relates
cancer treatment
Prior art date
Application number
PH12019501885A
Other languages
English (en)
Inventor
Kim Stuyckens
Ruixo Juan Jose Perez
Porre Peter Marie Z De
Anjali Narayan Avadhani
Yohann Loriot
Arlene O Siefker-Radtke
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12019501885(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2018/052694 external-priority patent/WO2018141921A1/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PH12019501885A1 publication Critical patent/PH12019501885A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
PH12019501885A 2017-02-06 2019-08-05 Cancer treatment PH12019501885A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (1)

Publication Number Publication Date
PH12019501885A1 true PH12019501885A1 (en) 2020-06-29

Family

ID=61094531

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019501885A PH12019501885A1 (en) 2017-02-06 2019-08-05 Cancer treatment

Country Status (25)

Country Link
US (2) US11077106B2 (enExample)
EP (2) EP3576740B1 (enExample)
JP (3) JP2020505425A (enExample)
KR (2) KR20250069693A (enExample)
CN (1) CN110198716A (enExample)
AU (2) AU2018216969B2 (enExample)
BR (1) BR112019016043A2 (enExample)
CA (1) CA3049737A1 (enExample)
DK (1) DK3576740T3 (enExample)
ES (1) ES2953005T3 (enExample)
FI (1) FI3576740T3 (enExample)
HR (1) HRP20230697T1 (enExample)
HU (1) HUE062453T2 (enExample)
IL (1) IL268463A (enExample)
JO (1) JOP20190190A1 (enExample)
LT (1) LT3576740T (enExample)
MX (2) MX2019009304A (enExample)
PH (1) PH12019501885A1 (enExample)
PL (1) PL3576740T3 (enExample)
RS (1) RS64778B1 (enExample)
SG (2) SG10202105110VA (enExample)
SI (1) SI3576740T1 (enExample)
SM (1) SMT202300233T1 (enExample)
TW (1) TWI874925B (enExample)
UA (1) UA126336C2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113957146A (zh) 2014-09-26 2022-01-21 詹森药业有限公司 使用fgfr突变基因组鉴定将对用fgfr抑制剂进行治疗有反应的癌症患者
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
PH12021551949A1 (en) * 2019-02-12 2022-07-18 Janssen Pharmaceutica Nv Cancer treatment
SG11202109902SA (en) * 2019-03-29 2021-10-28 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
SG11202109854RA (en) * 2019-03-29 2021-10-28 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
JOP20220182A1 (ar) * 2020-02-12 2023-01-30 Janssen Pharmaceutica Nv مثبطات كيناز تيروسين fgfr لعلاج سرطان المثانة الغازي غير العضلي عالي الخطورة
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症(covid-19)の予防または治療剤および医薬組成物
WO2024241297A1 (en) * 2023-05-24 2024-11-28 Janssen Pharmaceutica Nv Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان

Also Published As

Publication number Publication date
UA126336C2 (uk) 2022-09-21
JP7668777B2 (ja) 2025-04-25
SG11201907199QA (en) 2019-09-27
IL268463A (en) 2019-09-26
SG10202105110VA (en) 2021-06-29
SMT202300233T1 (it) 2023-09-06
LT3576740T (lt) 2023-08-10
TW202402290A (zh) 2024-01-16
AU2024201871A1 (en) 2024-04-11
MX2019009304A (es) 2019-09-19
PL3576740T3 (pl) 2023-09-11
AU2018216969B2 (en) 2024-04-11
AU2018216969A1 (en) 2019-07-25
DK3576740T3 (da) 2023-07-24
BR112019016043A2 (pt) 2020-03-31
EP4286005A3 (en) 2024-03-06
JP2020505425A (ja) 2020-02-20
CN110198716A (zh) 2019-09-03
JP2025024064A (ja) 2025-02-19
KR20250069693A (ko) 2025-05-19
JOP20190190A1 (ar) 2019-08-04
CA3049737A1 (en) 2018-08-09
TWI874925B (zh) 2025-03-01
SI3576740T1 (sl) 2023-10-30
US20220110935A1 (en) 2022-04-14
JP2023022190A (ja) 2023-02-14
MX2022007955A (es) 2022-07-27
HUE062453T2 (hu) 2023-11-28
US11077106B2 (en) 2021-08-03
RS64778B1 (sr) 2023-11-30
FI3576740T3 (fi) 2023-08-31
EP3576740B1 (en) 2023-06-14
KR20190110581A (ko) 2019-09-30
EP4286005A2 (en) 2023-12-06
HRP20230697T1 (hr) 2023-10-13
EP3576740A1 (en) 2019-12-11
ES2953005T3 (es) 2023-11-07
US20200022976A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
PH12019501885A1 (en) Cancer treatment
UA111530C2 (uk) Пластикова панель пвх
EA201991148A1 (ru) Половая панель и способ для производства половой панели
MX2022011263A (es) Elemento de recubrimiento de superficie decorativo, elemento de recubrimiento de superficie y procedimiento para producir un elemento de recubrimiento superficial decorativo.
MX2025002989A (es) Sistema de baldosas multiproposito, revestimiento de baldosas y baldosas
EA202191572A1 (ru) Декоративная панель и декоративное напольное покрытие, состоящее из указанных панелей
MY183576A (en) Mechanical locking system for floor panels
MX348146B (es) Panel acústico corrugado y método de producción.
NZ725305A (en) A suspended ceiling clip
MX2021001630A (es) Placa de yeso hecha de yeso que tiene un alto nivel de sal de cloruro y una lamina perforada y metodos asociados con esta.
EA202191590A1 (ru) Декоративная панель и декоративное напольное покрытие, состоящее из указанных панелей
PL3921178T3 (pl) Sposób wytwarzania folii dekoracyjnej i panelu zawierającego taką folię
MX2023012809A (es) Tienda modular.
ATE447495T1 (de) Fussboden-, wand- oder deckenpaneele sowie verfahren zu deren herstellung
MX2019004908A (es) Metodo para producir un panel de pared o piso decorado.
MX2024007292A (es) Panel decorativo y metodo para producir dicho panel.
EA202191573A1 (ru) Декоративная панель и декоративное напольное покрытие, состоящее из указанных панелей
ZA202304802B (en) Decorative panel, and covering of such decorative panels
WO2016044858A3 (en) Wall panel
MX2023007986A (es) Panel decorativo y revestimiento de suelo decorativo que consiste en dichos paneles.
MXPA03011601A (es) Tratamiento para el contorno de recubrimientos para pisos modulares.
CA154912S (en) Paper sheet
MY208310A (en) Use of bis(2-ethylhexyl) cyclohexane-1,4-dicarboxylate as plasticizer in surface coverings
TW200627519A (en) Substrate processing system
PL4221979T3 (pl) Panel, w szczególności panel podłogowy, sufitowy lub ścienny; pokrycie zbudowane z wielu takich paneli; i sposób recyklingu takiego panelu